Spots Global Cancer Trial Database for Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
Official Title: A Phase I Safety and Tolerability Study of Vorinostat in Combination With Sorafenib in Patients With Advanced Solid Tumors, With Exploration of Two Tumor-type Specific Expanded Cohorts at the Recommended Phase 2 Dose
Study ID: NCT00635791
Study Description
Brief Summary: This phase I trial studies the side effects and best dose of giving vorinostat and sorafenib tosylate together in treating patients with kidney or non-small cell lung cancer. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib tosylate may stop the growth of solid tumors by blocking blood flow to the tumor. Giving vorinostat together with sorafenib tosylate may kill more tumor cells.
Detailed Description: The main purpose of this study is to: * Evaluate the safety of vorinostat in combination with sorafenib. * Determine the largest dose of vorinostat + sorafenib that can be given safely to humans. * Determine if vorinostat + sorafenib are effective in stopping tumors from growing or in decreasing their size. * Study the side effects of vorinostat + sorafenib.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Colorado Cancer Center, Aurora, Colorado, United States
Contact Details
Name: David R Camidge, MD, PhD
Affiliation: University of Colorado, Denver
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
